Thermo Fisher Scientific has broken above prior resistance at $663.97, extending a technical advance that includes a 55-position climb over the past quarter in the SIA S&P 100 Index Report. The shares now rank 10, up three positions over the past month, alongside an SIA SMAX Score of 10/10.
The latest Point & Figure signal is a Spread Double Top. Following the breakout, the next resistance levels stand at $733.08 and $809.38. On the downside, 3-box reversal support is at $638.19, followed by further support at $544.69.
The sector backdrop has also improved. Health Services ranks 5 out of 31 in the SIA Sector Report after rising 12 positions over the past quarter and is classified as Favored. That sector improvement accompanies TMO’s own strengthening relative position.
Thermo Fisher has outperformed the iShares S&P 100 ETF Fund (OEF) across all three reported periods. The shares gained 6.41% monthly, 27.13% quarterly and 19.41% year to date, compared with benchmark advances of 1.43%, 2.63% and 11.61%, respectively. The quarterly gain is particularly notable alongside the substantial rise in report ranking, while the resistance break adds a recent price development to that broader improvement. Portfolio objectives and risk exposure remain the wider context for assessing these technical strengths.
Thermo Fisher Scientific provides products and services supporting life sciences research, laboratory operations, analytical testing, diagnostics, and the development and manufacture of therapies. The company has annual revenue exceeding $45 billion. Its brands include Thermo Scientific, Applied Biosystems, Invitrogen, Gibco, Fisher Scientific, Unity Lab Services, Patheon and PPD.
Disclaimer: SIACharts Inc. specifically represents that it does not give investment advice or advocate the purchase or sale of any security or investment whatsoever. This information has been prepared without regard to any particular investors investment objectives, financial situation, and needs. None of the information contained in this document constitutes an offer to sell or the solicitation of an offer to buy any security or other investment or an offer to provide investment services of any kind. As such, advisors and their clients should not act on any recommendation (express or implied) or information in this report without obtaining specific advice in relation to their accounts and should not rely on information herein as the primary basis for their investment decisions. Information contained herein is based on data obtained from recognized statistical services, issuer reports or communications, or other sources, believed to be reliable. SIACharts Inc. nor its third party content providers make any representations or warranties or take any responsibility as to the accuracy or completeness of any recommendation or information contained herein and shall not be liable for any errors, inaccuracies or delays in content, or for any actions taken in reliance thereon. Any statements nonfactual in nature constitute only current opinions, which are subject to change without notice.
